FDA Approves Tiratricol as First Treatment for Peripheral Thyrotoxicosis in MCT8 Deficiency

The U.S. Food and Drug Administration (FDA) has approved tiratricol (Emcitate) as the first-ever treatment for peripheral thyrotoxicosis in patients with monocarboxylate transporter 8 (MCT8) deficiency, also known as Allan-Herndon-Dudley syndrome. The approval, announced on September 29, 2026, is based on its ability to consistently lower T3 levels and improve heart rate and systolic blood pressure.